Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Extension Study of Lumasiran in Primary Hyperoxaluria Type 1
2016-003134-24Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1) and hyperoxaluria, sponsored by Alnylam Pharmaceuticals. Primary endpoint: Incidence of adverse events. Started Jul 2017; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)hyperoxaluria
Beyond the preview
Go deeper on 2016-003134-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003134-24.